

Jeffrey E Rubnitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2339578/publications.pdf>

Version: 2024-02-01

278
papers

21,314
citations

7551

77
h-index

11581

135
g-index

281
all docs

281
docs citations

281
times ranked

15023
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	1.7	5
2	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. <i>Blood Advances</i> , 2022, 6, 521-527.	2.5	10
3	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. <i>Journal of Clinical Oncology</i> , 2022, 40, 772-783.	0.8	7
4	Integrated Genomic Analysis Identifies <i>UBTF</i> Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 194-207.	2.6	38
5	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. <i>Blood Advances</i> , 2022, 6, 2824-2834.	2.5	3
6	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <i>FLT3</i> -Internal Tandem Duplication. <i>Clinical Cancer Research</i> , 2022, 28, 2536-2546.	3.2	3
7	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. <i>Leukemia</i> , 2022, 36, 1951-1960.	3.3	9
8	Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. <i>Leukemia</i> , 2021, 35, 2258-2273.	3.3	10
9	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	7.7	137
10	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. <i>Nature Communications</i> , 2021, 12, 985.	5.8	31
11	Activity of venetoclax against relapsed acute undifferentiated leukemia. <i>Cancer</i> , 2021, 127, 2608-2611.	2.0	0
12	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease-“Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	2.6	71
13	Global Proteomic Profiling of Pediatric AML: A Pilot Study. <i>Cancers</i> , 2021, 13, 3161.	1.7	6
14	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1009-1018.	0.6	40
15	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. <i>Blood Cancer Discovery</i> , 2021, 2, 586-599.	2.6	21
16	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	2.3	96
17	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>JAMA Network Open</i> , 2021, 4, e2128385.	2.8	6
18	Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML. <i>Blood</i> , 2021, 138, 3429-3429.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. <i>Blood</i> , 2021, 138, 4415-4415.	0.6	0
20	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3406-3406.	0.6	1
21	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. <i>Blood</i> , 2021, 138, 2295-2295.	0.6	0
22	Integrated Genomic Analysis Identifies UBTf Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, LBA-4-LBA-4.	0.6	0
23	78. Non-Invasive Prediction of Invasive Fungal Infection by Plasma-Based Microbial Cell-Free DNA Next-Generation Sequencing (mcfDNA NGS) in Pediatric Patients with Relapsed or Refractory Leukemia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S51-S51.	0.4	0
24	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 735-745.	3.3	56
25	Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. <i>JAMA Oncology</i> , 2020, 6, 552.	3.4	77
26	DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. <i>Cancers</i> , 2020, 12, 3024.	1.7	5
27	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	2.0	12
28	Vancomycin Heteroresistance and Clinical Outcomes in Bloodstream Infections Caused by Coagulase-Negative Staphylococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	13
29	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	5.1	92
30	Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection. <i>Clinical Chemistry</i> , 2020, 66, 518-522.	1.5	2
31	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2020, 136, 12-13.	0.6	2
32	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
33	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. <i>Blood</i> , 2020, 136, 23-24.	0.6	3
34	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2246-2256.	0.8	186
35	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	1.5	12
36	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2072-2081.	0.8	34

#	ARTICLE	IF	CITATIONS
37	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	0.8	169
38	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	3.2	14
39	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019, 10, 2189.	5.8	26
40	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		74
41	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. <i>Pharmacogenomics Journal</i> , 2019, 19, 305-314.	0.9	9
42	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	0.6	24
43	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. <i>Blood</i> , 2019, 134, 918-918.	0.6	1
44	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10004-10004.	0.8	3
45	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 414-423.	2.3	44
46	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 379-379.	0.6	1
47	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 178-178.	0.6	0
48	A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. <i>Blood</i> , 2019, 134, 1429-1429.	0.6	1
49	Bone mineral density in children with acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 1025-1035.	2.0	21
50	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	5
51	Universal monitoring of minimal residual disease in acute myeloid leukemia. <i>JCI Insight</i> , 2018, 3, .	2.3	60
52	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	18.7	236
53	POST: A framework for set-based association analysis in high-dimensional data. <i>Methods</i> , 2018, 145, 76-81.	1.9	1
54	Acute Myeloid Leukemia in Children. , 2018, , 981-993.		1

#	ARTICLE	IF	CITATIONS
55	Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. <i>Pharmacogenomics</i> , 2018, 19, 1101-1110.	0.6	7
56	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 854-863.	4.6	43
57	Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study. <i>Blood</i> , 2018, 132, 655-655.	0.6	3
58	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2018, 132, 3966-3966.	0.6	5
59	Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients. <i>Blood</i> , 2018, 132, 1536-1536.	0.6	5
60	Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS10575-TPS10575.	0.8	1
61	Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 26711-26723.	0.8	26
62	Genome-wide association analysis identifies SNPs predictive of <i>in vitro</i> leukemic cell sensitivity to cytarabine in pediatric AML. <i>Oncotarget</i> , 2018, 9, 34859-34875.	0.8	12
63	Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts. <i>Blood</i> , 2018, 132, 290-290.	0.6	1
64	Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML. <i>Blood</i> , 2018, 132, 2758-2758.	0.6	2
65	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017, 58, 247-250.	0.6	5
66	Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. <i>Cancer</i> , 2017, 123, 3602-3608.	2.0	11
67	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26632.	0.8	3
68	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	0.7	17
69	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. <i>Cancer</i> , 2017, 123, 3791-3798.	2.0	34
70	RelA Mutant <i>Enterococcus faecium</i> with Multiantibiotic Tolerance Arising in an Immunocompromised Host. <i>MBio</i> , 2017, 8, .	1.8	72
71	Current Management of Childhood Acute Myeloid Leukemia. <i>Paediatric Drugs</i> , 2017, 19, 1-10.	1.3	64
72	Infection-related complications during treatment for childhood acute lymphoblastic leukemia. <i>Annals of Oncology</i> , 2017, 28, 386-392.	0.6	115

#	ARTICLE	IF	CITATIONS
73	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. <i>Leukemia</i> , 2017, 31, 333-339.	3.3	140
74	Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 373-381.	2.3	40
75	POST: A framework for set-based association analysis in high-dimensional data. , 2017, , .		0
76	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2017, 128, 369-380.	3.9	39
77	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1546-1551.	0.8	29
78	Evaluation of artemisinins for the treatment of acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1231-1243.	1.1	41
79	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4094-4101.	0.8	93
80	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016, 48, 1551-1556.	9.4	215
81	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 651-660.	2.3	27
82	Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. <i>Leukemia</i> , 2016, 30, 1184-1187.	3.3	39
83	Clinical significance of <i>in vivo</i> cytarabine-induced gene expression signature in AML. <i>Leukemia and Lymphoma</i> , 2016, 57, 909-920.	0.6	7
84	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 179-179.	0.6	0
85	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	0.6	0
86	Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0135904.	1.1	9
87	Clinical Impact of Additional Cytogenetic Aberrations, <i>cKIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 4247-4258.	0.8	75
88	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-615.	0.8	56
89	Natural killer cell therapy in children with relapsed leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1468-1472.	0.8	39
90	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology</i> , The, 2015, 16, 465-474.	5.1	177

#	ARTICLE	IF	CITATIONS
91	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	0.8	277
92	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	1.2	31
93	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML. <i>Blood</i> , 2015, 126, 1345-1345.	0.6	2
94	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. <i>Blood</i> , 2015, 126, 4872-4872.	0.6	3
95	The methylome of pediatric acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10027-10027.	0.8	1
96	Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2434-2434.	0.6	0
97	New approaches for the immunotherapy of acute myeloid leukemia. <i>Discovery Medicine</i> , 2015, 19, 275-84.	0.5	18
98	Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?. <i>Expert Review of Hematology</i> , 2014, 7, 427-429.	1.0	12
99	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 1985-1992.	2.0	53
100	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2014, 120, 1514-1519.	2.0	58
101	A revised definition for cure of childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 2336-2343.	3.3	113
102	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 949-959.	0.8	275
103	Definition of cure in childhood acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 2490-2496.	2.0	12
104	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. <i>Haematologica</i> , 2014, 99, 299-307.	1.7	34
105	An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Children's Oncology Group Protocols AAML0531 and 03P1 and St Jude Children's Research Hospital Protocol AML02. <i>Blood</i> , 2014, 124, 277-277.	0.6	2
106	Targeted Inhibition of the MLL Transcriptional Complex By Proteasome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. <i>Blood</i> , 2014, 124, 972-972.	0.6	8
107	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 3722-3722.	0.6	0
108	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. <i>Blood</i> , 2014, 124, 481-481.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 369-378.	1.1	36
110	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 4036-4043.	2.0	41
111	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 2061-2066.	2.0	27
112	Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. <i>Leukemia</i> , 2013, 27, 731-734.	3.3	41
113	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1161-1164.	0.8	22
114	Voriconazole Prophylaxis in Children With Cancer. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e451-e455.	1.1	23
115	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5758-5768.	3.2	87
116	Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 1620-1627.	3.2	58
117	<i>RRM1</i> and <i>RRM2</i> pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. <i>Pharmacogenomics</i> , 2013, 14, 1449-1466.	0.6	27
118	Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. <i>Blood</i> , 2013, 121, 4366-4376.	0.6	42
119	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group. <i>Blood</i> , 2013, 122, 2704-2713.	0.6	86
120	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. <i>Blood</i> , 2013, 122, 490-490.	0.6	0
121	Ontogeny and Sorafenib Metabolism. <i>Clinical Cancer Research</i> , 2012, 18, 5788-5795.	3.2	40
122	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. <i>Journal of Clinical Oncology</i> , 2012, 30, 2005-2012.	0.8	104
123	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. <i>Leukemia</i> , 2012, 26, 265-270.	3.3	112
124	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 119, e67-e75.	0.6	66
125	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5980-5988.	0.6	80
126	Childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 259-276.	1.2	68

#	ARTICLE	IF	CITATIONS
127	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. <i>Blood</i> , 2012, 120, 468-472.	0.6	176
128	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 683-697.	7.7	213
129	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3625-3632.	0.8	188
130	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 921-929.	1.9	54
131	Effect of body mass index on the outcome of children with acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 5989-5996.	2.0	56
132	Treatment outcome in older patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 6253-6259.	2.0	32
133	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>British Journal of Haematology</i> , 2012, 156, 275-279.	1.2	16
134	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Munster AML Study Group. <i>Blood</i> , 2012, 120, 2516-2516.	0.6	0
135	Isolated Nasal Septum Necrosis Caused by <i>Aspergillus flavus</i> in an Immunocompromised Child. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 627-629.	1.1	6
136	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	0.6	58
137	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. <i>Blood</i> , 2011, 118, 223-230.	0.6	157
138	Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. <i>Leukemia</i> , 2011, 25, 1354-1356.	3.3	19
139	Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 1321-1329.	0.4	21
140	Spinal epidural lipomatosis in children with hematologic malignancies. <i>Annals of Hematology</i> , 2011, 90, 1067-1074.	0.8	10
141	Randomized trial of 2 dosages of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 1313-1320.	2.0	13
142	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. <i>Pharmacogenomics</i> , 2011, 12, 327-339.	0.6	27
143	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 386-391.	0.8	122
144	IDH1 and IDH2 mutations in pediatric acute leukemia. <i>Leukemia</i> , 2011, 25, 1570-1577.	3.3	80

#	ARTICLE	IF	CITATIONS
145	Genetic Variants in Cytosolic 5â€²-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 9-23.	1.3	50
146	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3293-3300.	0.8	142
147	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2011, 103, 893-905.	3.0	50
148	Acute Megakaryoblastic Leukemia Without <i>GATA1</i> Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e230-e233.	0.8	15
149	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital â€” Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 757-757.	0.6	7
150	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. <i>Cancer</i> , 2010, 116, 98-105.	2.0	24
151	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. <i>Blood</i> , 2010, 116, 2644-2650.	0.6	141
152	Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. <i>European Journal of Paediatric Neurology</i> , 2010, 14, 78-79.	0.7	13
153	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2010, 24, 371-382.	3.3	248
154	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5499-5510.	3.2	71
155	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 955-959.	0.8	563
156	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 543-552.	5.1	514
157	Acute Myeloid Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 35-63.	0.9	123
158	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1073-1073.	0.6	3
159	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 498-498.	0.6	0
160	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. <i>Blood</i> , 2010, 116, 849-849.	0.6	0
161	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. <i>Blood</i> , 2010, 116, 495-495.	0.6	1
162	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12944-12949.	3.3	172

#	ARTICLE	IF	CITATIONS
163	PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. <i>Bioinformatics</i> , 2009, 25, 2013-2019.	1.8	15
164	Cutaneous Infection Caused by <i>Macrophomina phaseolina</i> in a Child with Acute Myeloid Leukemia. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1969-1972.	1.8	32
165	Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. <i>Leukemia</i> , 2009, 23, 402-404.	3.3	37
166	Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 245-250.	3.3	40
167	Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. <i>Leukemia</i> , 2009, 23, 1410-1416.	3.3	53
168	Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. <i>Leukemia</i> , 2009, 23, 1406-1409.	3.3	128
169	Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia. <i>European Journal of Oncology Nursing</i> , 2009, 13, 156-163.	0.9	38
170	Minimal Residual Disease Quantitation in Acute Myeloid Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S281-S285.	1.4	42
171	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. <i>New England Journal of Medicine</i> , 2009, 360, 2730-2741.	13.9	1,059
172	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. <i>Lancet Oncology</i> , 2009, 10, 147-156.	5.1	850
173	Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. <i>Blood</i> , 2009, 113, 5083-5089.	0.6	159
174	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. <i>Blood</i> , 2009, 114, 3764-3768.	0.6	78
175	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	0.6	383
176	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2009, 114, 114-114.	0.6	3
177	Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. <i>Blood</i> , 2009, 114, 16-16.	0.6	0
178	5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2009, 114, 593-593.	0.6	0
179	Childhood Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2008, 9, 95-105.	1.3	27
180	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 542-548.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Baseline mannose binding lectin levels may not predict infection among children with leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 866-868.	0.8	10
182	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. <i>Cancer</i> , 2008, 113, 376-382.	2.0	87
183	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. <i>Cancer</i> , 2008, 113, 522-529.	2.0	83
184	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1110-1120.	1.9	43
185	Acute Myeloid Leukemia. <i>Pediatric Clinics of North America</i> , 2008, 55, 21-51.	0.9	54
186	Prospective Analysis of <i>TEL</i> Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2186-2191.	0.8	79
187	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1207.	3.8	261
188	Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 935-945.	1.3	76
189	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet</i> , 2007, 370, 240-250.	6.3	547
190	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	0.6	413
191	Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. <i>Cancer</i> , 2007, 109, 157-163.	2.0	85
192	Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude experience. <i>Pediatric Blood and Cancer</i> , 2007, 48, 10-15.	0.8	46
193	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
194	Acute myeloid leukemia. , 2006, , 499-539.		2
195	Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2006, 108, 3302-3304.	0.6	85
196	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. <i>Blood</i> , 2006, 108, 3997-4002.	0.6	89
197	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. <i>Pediatric Blood and Cancer</i> , 2006, 47, 931-935.	0.8	51
198	Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the <i>ETV6</i> “ <i>RUNX1</i> fusion, T-lineage immunophenotype, and favorable outcome. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 50-57.	1.0	44

#	ARTICLE	IF	CITATIONS
199	Impact of age on outcome of pediatric acute myeloid leukemia. <i>Cancer</i> , 2006, 106, 2495-2502.	2.0	52
200	Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 4474-4474.	0.6	2
201	Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation. <i>Leukemia</i> , 2005, 19, 1399-1403.	3.3	39
202	Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. <i>Leukemia</i> , 2005, 19, 2125-2129.	3.3	53
203	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2005, 103, 368-376.	2.0	79
204	Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2005, 44, 138-141.	0.8	20
205	Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2005, 44, 63-69.	0.8	35
206	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 7936-7941.	0.8	70
207	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2005, 105, 4752-4758.	0.6	205
208	Gene expression profiling of pediatric acute myelogenous leukemia. <i>Blood</i> , 2004, 104, 3679-3687.	0.6	404
209	Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia</i> , 2004, 18, 1072-1077.	3.3	61
210	Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. <i>Leukemia</i> , 2004, 18, 1581-1586.	3.3	23
211	Death during induction therapy and first remission of acute leukemia in childhood. <i>Cancer</i> , 2004, 101, 1677-1684.	2.0	126
212	Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. <i>Leukemia Research</i> , 2004, 28, 349-352.	0.4	19
213	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIII B at St Jude Children's Research Hospital. <i>Blood</i> , 2004, 104, 2690-2696.	0.6	412
214	Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 3084-3091.	0.8	180
215	Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 123, 243-252.	1.2	122
216	Urolithiasis in pediatric patients with acute lymphoblastic leukemia. <i>Leukemia</i> , 2003, 17, 541-546.	3.3	25

#	ARTICLE	IF	CITATIONS
217	Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. <i>Leukemia</i> , 2003, 17, 2090-2096.	3.3	75
218	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. <i>Cancer Treatment Reviews</i> , 2003, 29, 31-44.	3.4	43
219	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2001.	3.8	155
220	MRD in AML: it's time to face the FACS. <i>Blood</i> , 2003, 101, 3341-3341.	0.6	1
221	Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 4217-4224.	0.8	65
222	Risk Factors for Traumatic and Bloody Lumbar Puncture in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2001.	3.8	136
223	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 2302-2309.	0.8	173
224	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. <i>Current Opinion in Hematology</i> , 2002, 9, 345-352.	1.2	61
225	Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 561-565.	0.3	22
226	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 43-47.	0.6	45
227	Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 52-58.	0.6	240
228	Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 2399-2402.	0.6	171
229	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 419-428.	1.1	43
230	Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. <i>Leukemia</i> , 2002, 16, 2072-2077.	3.3	73
231	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 2302-2309.	0.8	85
232	Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. <i>Blood</i> , 2001, 97, 3727-3732.	0.6	192
233	Second malignancy after treatment of childhood non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 92, 1959-1966.	2.0	59
234	Second malignancy after treatment of childhood acute myeloid leukemia. <i>Leukemia</i> , 2001, 15, 41-45.	3.3	34

#	ARTICLE	IF	CITATIONS
235	Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. <i>Leukemia</i> , 2001, 15, 891-897.	3.3	102
236	Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. <i>Leukemia</i> , 2001, 15, 1326-1330.	3.3	30
237	Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10338-10343.	3.3	57
238	Safety of Lumbar Puncture for Children With Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 2222.	3.8	156
239	Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 227-232.	1.5	15
240	Prognostic factors in infants with acute myeloid leukemia. <i>Leukemia</i> , 2000, 14, 684-687.	3.3	82
241	Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. <i>Leukemia</i> , 2000, 14, 2286-2294.	3.3	187
242	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000, 96, 3381-3384.	0.6	180
243	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000, 96, 2691-2696.	0.6	406
244	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 3273-3279.	0.8	213
245	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 1525-1532.	0.8	155
246	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000, 96, 2691-2696.	0.6	14
247	Childhood Acute Lymphoblastic Leukemia With the <i>MLL-ENL</i> Fusion and t(11;19)(q23;p13.3) Translocation. <i>Journal of Clinical Oncology</i> , 1999, 17, 191-191.	0.8	102
248	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 818-818.	0.8	128
249	Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. <i>Leukemia</i> , 1999, 13, 19-21.	3.3	78
250	Significance of the TEL-AML1 fusion gene in childhood AML. <i>Leukemia</i> , 1999, 13, 1470-1471.	3.3	10
251	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 1999, 1, 253-261.	2.3	37
252	High incidence of secondary brain tumours after radiotherapy and antimetabolites. <i>Lancet</i> , The, 1999, 354, 34-39.	6.3	390

#	ARTICLE	IF	CITATIONS
253	Molecular diagnostics in the treatment of leukemia. <i>Current Opinion in Hematology</i> , 1999, 6, 229.	1.2	18
254	Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis. <i>Blood</i> , 1999, 93, 315-320.	0.6	1
255	Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. <i>Leukemia</i> , 1998, 12, 675-681.	3.3	75
256	BCL6 rearrangement and mediastinal involvement in a case of B cell acute lymphoblastic leukemia. <i>Leukemia</i> , 1998, 12, 1163-1165.	3.3	3
257	Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 1998, 12, 1176-1181.	3.3	127
258	Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. <i>Leukemia</i> , 1998, 12, 1764-1770.	3.3	84
259	Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. <i>Lancet, The</i> , 1998, 351, 550-554.	6.3	402
260	Molecular Genetics of Childhood Leukemias. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 1-11.	0.3	58
261	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3768-3773.	0.8	89
262	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998, 92, 411-415.	0.6	183
263	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998, 92, 411-415.	0.6	6
264	Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 1997, 4, 233-241.	1.2	19
265	TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1150-1157.	0.8	198
266	Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study. <i>Blood</i> , 1997, 89, 1143-1146.	0.6	91
267	Lack of ETV6 (TEL) gene rearrangements or p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. <i>Leukemia</i> , 1997, 11, 979-983.	3.3	10
268	Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. <i>Leukemia</i> , 1997, 11, 1201-1206.	3.3	85
269	Childhood Acute Lymphoblastic Leukemia. <i>Oncologist</i> , 1997, 2, 374-380.	1.9	21
270	Correction of deletions in mammalian cells by gene conversion. <i>Somatic Cell and Molecular Genetics</i> , 1987, 13, 183-190.	0.7	10

#	ARTICLE	IF	CITATIONS
271	Extrachromosomal and chromosomal gene conversion in mammalian cells.. Molecular and Cellular Biology, 1986, 6, 1608-1614.	1.1	54
272	Rapid assay for extrachromosomal homologous recombination in monkey cells.. Molecular and Cellular Biology, 1985, 5, 529-537.	1.1	69
273	Recombination events after transient infection and stable integration of DNA into mouse cells.. Molecular and Cellular Biology, 1985, 5, 659-666.	1.1	102
274	Somatic recombination of the rDNA chromosomal region in diploids and dikaryons of Schizophyllum commune. Experimental Mycology, 1985, 9, 122-132.	1.8	3
275	The minimum amount of homology required for homologous recombination in mammalian cells.. Molecular and Cellular Biology, 1984, 4, 2253-2258.	1.1	280
276	Constitutive behavior of methionyl-tRNA synthetase compared to repressible behavior of methionine adenosyltransferase in mammalian cells. Biochimica Et Biophysica Acta - General Subjects, 1981, 677, 269-273.	1.1	4
277	Acute myeloid leukemia. , 0, , 395-420.		1
278	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0